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ABSTRACT: The nitration of azolo[1,5-a]pyrimidin-7-amines
with several nitration agents (such as acetic nitric anhydride,
nitronium tetrafluoroborate, and a mixture of concentrated nitric
acid and sulfuric acid) has been investigated. It has been shown that,
depending on the conditions, the nitration of pyrazolopyrimidin-7-
amines bearing electron-withdrawing groups in the pyrazole ring
leads to nitration products in the pyrimidine and/or pyrazole ring.
The nitration of triazolo[1,5-a]pyrimidin-7-amines with “nitrating
mixture” has been optimized, thus allowing us to obtain a series of
6-nitro[1,2,4]triazolo[1,5-a]pyrimidin-7-amines, followed by their
reduction into the corresponding [1,2,4]triazolo[1,5-a]pyrimidin-
6,7-diamines (yields 86−89%). The latter have been subjected to
heterocyclization by a variety of electrophilic compounds (such as
CS2, glyoxal, triethyl orthoformate) with the formation of five- or six-membered annulated cycles.
■ INTRODUCTION
Polycyclic systems containing the pyrimidine ring have long
been attracting attention of chemists due to a remarkable role
played by many fused pyrimidines (purines, pteridines, and
other derivatives) in biology and drug design. During the last
decade, the synthesis and properties of azolo[1,5-a]-
pyrimidines have the most actively been studied. Indeed,
according to the SciFinder database, more than 1000 original
papers and patents have been published over the last 5 years
(2015−2019), thus indicating great interest in this class of
compounds. These azolo[1,5-a]-pyrimidines have been found
to exhibit antiviral, anti-inflammatory, antibacterial, antifungal,
antiparasitic, antitumor, and other biological activities.1
At the same time, reports on the synthesis of fused
polycyclic derivatives, bearing the core fragment of azolo[1,5-
a]pyrimidines, remain scarcely presented in the literature, and
a limited number of synthetic methods for obtaining of
azolo[b]purines have so far been described.2
Another important class of fused pyrimidines of natural
origin is presented by pteridines, which are known to act as
immune system activators, pigments, and enzyme cofactors,
while their synthetic derivatives proved to exhibit various types
of biological activity.3
A few research studies dedicated to azolo-annulated
pteridines have been carried out during recent years. They
include the synthesis of azolo-annulated [1,5-c,f ], [3,4-b], [4,3-
a,c,e,f,g] pteridines, as well as the series of azolo[1,5-
a]tetrahydropyrazines.4 There are experimental data on anti-
inflammatory and antibacterial activities of pyrazolo[4.3-
g]pteridines;4b 7-amino-azolo[4,3-f ]- and [1,5-f ]pteridinones
have been established to be antitumour agents,4c while 4,5-
dihydro[1,2,4]triazolo[4,3-f ]pteridines are known to act as
inhibitors of the BRD4 chromatin-binding protein,5 which is a
biological target for many diseases, including cancer,6
inflammation,7 diabetes,8 and viral infections.9 These data
demonstrate an extremely wide range of plausible therapeutic
applications of these compounds.4d However, the data on the
synthesis and biological activity of the azolo[1,5-a]pteridines
remain to be scarcely available.
Therefore, the development of new methods for the
synthesis of annulated derivatives of azolo[1,5-a]pyrimidines
appears to be a relevant task for organic and medicinal
chemistry. We have developed earlier a synthetic approach to
azolo[1,5-a]pyrimidine-7-amines, which were used as starting
materials in the present work.10
■ RESULTS AND DISCUSSION
It is well known that the direct incorporation of the nitro group
into the pyrimidine ring usually requires the presence of several
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electron-donating groups. Indeed, it has been shown by
Makisumi that the nitration of [1,2,4]triazolo[1,5-a]pyrimidin-
7-amine (1a) with fuming nitric acid in the presence of sulfuric
and acetic acids at 10−15 °C does not lead to the desired
product.11 However, Lynch et al. have reported the successful
nitration of pyrazolo[1,5-a]pyrimidine with acetyl nitrate (a
mixture of fuming nitric acid and acetic anhydride) at 5−10
°C, leading to 6-nitropyrazolo[1,5-a]pyrimidine,12 which
indicates that the appropriate nitration conditions can also
be selected for 1,2,4-triazolo[1,5-a]pyrimidine-7-amine (1a).
Since attempts to use acetyl nitrate and nitronium
tetrafluoroborate as nitration agents have failed, we have
selected a mixture of HNO3 and H2SO4 in the ratio 1:6, where
an excess of sulfuric acid reduces the oxidizing properties of
nitric acid while also contributing to its complete conversion to
a nitronium cation (Scheme 1).
We have found that an increase in the reaction time up to 24
h at room temperature does not afford the target nitration
product (only trace quantities of the latter are formed).
However, the optimization of the reaction temperature has
allowed us to obtain the desired product 2a in high yield and
reduce significantly the reaction time without provoking
secondary processes at a wide temperature interval. Conditions
6 (Table 1) appear to be optimal and can be used for the
nitration of triazolopyrimidines 1b−d (Scheme 2).
In all cases, the nitration process proceeds smoothly,
affording the target products in good yields. No oxidation of
the amino group has been observed, thus allowing to avoid the
application of any protective groups. In the case of
azolopyrimidine 1b, the methylthio group is completely
oxidized into the corresponding sulfone 2b under the
described conditions, while a smaller excess of the nitrating
mixture causes the formation of a mixture of methyl sulfoxide
and methyl sulfonyl derivatives (for details, see Supporting
Information S50 and S51).
Under the same reaction conditions, the nitration of
pyrazolopyrimidine-7-amines 3a,b (Scheme 3) bearing elec-
tron-withdrawing groups in the pyrazole ring (Table 1, entry
6) leads to nitration products on the pyrimidine and pyrazole
rings (Scheme 3a), even at room temperature for 3 h.
We also found that treatment of 3a with an excess of
nitration mixture (2 equiv) using potassium nitrate leads
exclusively to the nitration product according to the pyrazole
ring 5 (compound 5 have been previously described13); the
use of acetyl nitrate as a nitrating agent made it possible to
selectively obtain the nitration product in the pyrimidine ring 6
(Scheme 3b).
In the literature, cases described of such pyrazole behavior
contained an ethoxycarbonyl fragment in the third position of
the ring.14 Presumably, the reaction mechanism consists in the
hydrolysis of the corresponding carboxyl derivative, its
decarboxylation, and subsequent nitration; this is indirectly
confirmed by the discovery of trace amounts of amide and
decarboxylated derivatives in the mass spectra of compounds 4
and 5 (for details, see Supporting Information S41−S48).
Subsequent reduction of the obtained nitro derivatives 2a−d
in an H2 atmosphere at a pressure of 5 bar with a Pd/C (5%)
catalyst leads to the formation of the corresponding
heteroaromatic diamines 7a−d with high yields (86−89%)
(Scheme 4).
Thus, we have proposed methods for obtaining a number of
diamines 7 not previously described in the literature, which can
act as “building blocks” in the synthesis of condensed systems
containing a triazolo[1,5-a]pyrimidine fragment.
Subsequently, we examined the synthetic potential of the
obtained heteroaromatic 1,2-diamines.
It was found that the boiling of diamines 7 in formic acid
(97%), which ceases at the stage of formylation of the amino
group in position 6, does not lead to the formation of an
annulated imidazole ring. However, according to the literature,
Scheme 1. Nitration of [1,2,4]Triazolo[1,5-a]pyrimidin-7-
amine (1a)
Table 1. Nitration Reaction Parameters
entry nitration agent T (°C) time (h) yield (%)a
1 HNO3/Ac2O (1:2) rt 3 nr
b
2 NO2BF4 in acetonitrile rt 24 nr
b
3 NO2BF4 in acetonitrile 82 12 nr
b
4 3 equiv HNO3/H2SO4 (1:6)
d rt 24 tracec
5 3 equiv HNO3/H2SO4 (1:6)
d 60 15 89
6 3 equiv HNO3/H2SO4 (1:6)
d 80 4 92
7 3 equiv HNO3/H2SO4 (1:6)
d 100 3 87
aIsolated yield. bnr = no reaction. cDetected by TLC. dMolar ratio.
Scheme 2. Nitration of [1,2,4]Triazolo[1,5-a]pyrimidin-7-
amines (1a−d)
Scheme 3. Nitration of Pyrazolo[1,5-a]pyrimidine-7-amines
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this approach has been successfully implemented for related
structures containing an alkylamino group at position 7 of a
heterocyclic system.2c Another method presented in the
literature is the interaction of pyrazolo[1,5-a]pyrimidin-6,7-
diamines with orthoesters under microwave activation and in
the absence of the solvent.2a As an alternative to this approach,
we propose a synthesis method (Scheme 5) that does not
require microwave activation, consisting of the cyclocondensa-
tion of [1,2,4]triazolo[1,5-a]pyrimidine-6,7-diamines (7) with
triethyl orthoformate in acetic acid. Target products 8a−d
were isolated with high yields (71−91%).
In this case, the optimal conditions for obtaining the
structures 8 consist in cyclization with triethyl orthoformate
(300 mol %) in glacial acetic acid (in the case of 8b a mixture
of acetic acid with DMF), with the use of a smaller amount of
orthoester, leading to the formation of acylation products.
The possibility of one-pot cyclization of diamines 7 with
carbon disulfide followed by the selective alkylation of the
formed thiones to the corresponding derivatives 9 (Scheme 6)
was also shown.
Only one example of the synthesis of related structures can
be found in the literature, in which the authors claim that
alkylation proceeds exclusively at the nitrogen atom in the 3
position; however, this contradicts the data obtained by us.2b
Using the 1H−13C HSQC and 1H−13C HMBC correlation
methods with the example of compound 9c, it is shown that
the alkylation proceeds at the sulfur atom (Figure 1; for details,
see Supporting Information S33−S38).
In the spectrum of 1H−13C HSQC, the position of signals of
the carbon atoms of the isobutyl substituent was uniquely
determined: methyl (21.4 ppm), methine (28.0 ppm), and
methylene (39.7 ppm), whose protons have characteristic
signals in the 1H spectra. The signal of the C-4 atom (141.1
ppm), which interacts with the singlet of the pyrimidine proton
H-4 (9.14 ppm), was also established.
The position of the signals of atoms C-5a (153.2 ppm), C-1a
(144.6 ppm), and C-3a (122.1 ppm) was established using the
spectrum of 1H−13C HMBC according to the presence of
interaction with the H-4 proton signal, which can be identified
due to the special features of the environment. Under the
condition of alkylation on one of the nitrogen atoms of the
imidazole ring in the HMBC spectrum, the interaction of the
methylene proton signal of the isobutyl substituent with the
signal of the C-1a (144.6 ppm) or C-3a (122.1 ppm) atom
would be observed; however, only the interaction with the
signal of the C-2 atom (156.9 ppm) is additionally detected for
these protons. From the foregoing, we can form an
unambiguous conclusion about the presence of a structure
having an alkyl substituent at the sulfur atom.
Using the example of diamine 7b, the possibility of
synthesizing 2H-[1,2,4]triazolo[1,5-a][1,2,3]triazolo[4,5-e]-
pyrimidinine is shown as a result of diazotization, followed
by subsequent intramolecular azo coupling (Scheme 7). The
alternative approach proposed by us for the synthesis of this
heterocyclic system is especially relevant due to being
previously presented in the literature in a single example.15
Scheme 4. Reduction of 6-Nitro-[1,2,4]triazolo[1,5-
a]pyrimidin-7-amines (2a−d) in the Pd/C−H2 System
Scheme 5. Synthesis of Triazolo[5,1-b]purines
Scheme 6. One-Pot Synthesis of Compounds 9a−d
Figure 1. Key interactions in 1H−13C HSQC and 1H−13C HMBC
spectra of compound 9c (δ, ppm).
Scheme 7. Example of the Synthesis of Azolo Azapurine 10
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As noted earlier, no data on the synthesis and properties of
azolo[1,5-a]pteridines are available in the literature. In this
connection, we developed a method for the synthesis of these
systems, involving cyclocondensation of diamines 7 with
glyoxal (Scheme 8).
In all cases, heterocyclization proceeds smoothly and with
high yields (76−89%). In the absence of acid catalysis, the
reaction is complicated by the formation of a poorly soluble
precipitate, the main component of which is comprised of the
dimeric derivative of the starting diamine (for details, see
Supporting Information S52 and S53).
■ CONCLUSIONS
Thus, we have developed a method for the synthesis of 6,7-
diamino-1,2,4-triazolo[1,5-a]pyrimidines, which are conven-
ient matrixes for the construction of various kinds of
polynuclear condensed systems of interest as materials for
medicine and technology.
■ EXPERIMENTAL SECTION
One-dimensional 1H, 13C, and 19F NMR spectra as well as two-
dimensional 1H−13C HSQC and 1H−13C HMBC experiments
were acquired on a Bruker DRX-400 instrument (400, 101,
and 376 MHz, respectively), a Bruker DRX-500 instrument
(500, 126, and 470 MHz, respectively) or a Bruker Avance
NEO 600 instrument (600 and 151 MHz, respectively),
equipped with a Prodigy broadband gradient cryoprobe using
DMSO-d6 as a solvent and TMS as an internal standard. High-
resolution mass spectrometry (HRMS) was performed using a
Bruker Daltonik MaXis Impact HD quadrupole time-of-flight
mass spectrometer (positive (POS)/negative (NEG) electro-
spray ionization or atmospheric-pressure chemical ionization
from the MeCN or MeCN/DMSO solution, at a flow rate of
180 μL·h−1 with parameters optimized for small molecule
detection based on a preinstalled method for infusion analysis).
Elemental analysis was performed on a PerkinElmer PE 2400
elemental analyzer. Melting points were determined in open
capillaries using a Stuart SMP3 apparatus. All solvents and
commercially available reactants/reagents were used as
received. Noncommercial starting materials were prepared as
described below or according to the literature procedures.
General Procedure for the Synthesis of Compounds
2a−d. The corresponding triazolopyrimidine-7-amine 1a−d
(10 mmol) was added portionwise to a mixture of 1.25 mL (30
mmol) of fuming HNO3 and 9.60 mL (180 mmol) of
concentrated H2SO4 with stirring and cooling (ice bath). The
reaction mixture was gradually heated to 80 °C under reflux
and kept for 4 h, then cooled to room temperature, poured
into ice, and carefully neutralized with aqueous ammonia to
pH ∼ 7. The precipitate was filtered off, thoroughly washed
with H2O, and air-dried.
6-Nitro-[1,2,4]triazolo[1,5-a]pyrimidine-7-amine (2a).
Obtained from 1a (1.35 g, 10 mmol, 1 equiv) in a mixture
of fuming HNO3 (1.25 mL, 30 mmol, 3 equiv) and H2SO4
(9.60 mL, 180 mmol, 18 equiv). Pale yellow solid; 1.65 g, 92%
yield; mp 263−265 °C. 1H NMR (DMSO-d6, 400 MHz): δ
8.65 (s, 1H), 9.22 (s, 1H), δ 9.51 (br s, 2H). 13C{1H} NMR
(DMSO-d6, 101 MHz): δ 118.4, 145.9, 152.1, 155.7, 156.2.
Anal. calcd for C5H4N6O2: C, 33.34; H, 2.24; N, 46.66. Found:
C, 33.24; H, 2.06; N, 46.53.
2-(Methylsulfonyl)-6-nitro-[1,2,4]triazolo[1,5-a]-
pyrimidine-7-amine (2b). Obtained from 1b (1.81 g, 10
mmol, 1 equiv) in a mixture of fuming HNO3 (1.25 mL, 30
mmol, 3 equiv) and H2SO4 (9.60 mL, 180 mmol, 18 equiv).
White solid; 2.16 g, 84% yield; mp 265−267 °C. 1H NMR
(DMSO-d6, 400 MHz): δ 3.51 (s, 3H), 9.31 (s, 1H), 9.44 (br
s, 2H). 13C{1H} NMR (DMSO-d6, 126 MHz): δ 41.8, 119.7,
146.6, 153.9, 156.2, 164.8. Anal. calcd for C6H6N6O4S: C,
27.91; H, 2.34; N, 32.55. Found: C, 28.12; H, 2.41; N, 32.58.
6-Nitro-2-(trifluoromethyl)-[1,2,4]triazolo[1,5-a]-
pyrimidine-7-amine (2c) + H2O. Obtained from 1c (2.03 g, 10
mmol, 1 equiv) in a mixture of fuming HNO3 (1.25 mL, 30
mmol, 3 equiv) and H2SO4 (9.60 mL, 180 mmol, 18 equiv).
White solid; 2.32 g, 87% yield; mp 233−235 °C. 1H NMR
(DMSO-d6, 400 MHz): δ 9.34 (s, 1H), 9.99 (br s, 2H).
13C{1H} NMR (DMSO-d6, 101 MHz): δ 118.9 (q, J = 271.0
Hz), 119.6, 146.4, 153.7, 155.6 (q, J = 39.2 Hz), 156.4. 19F
NMR (DMSO-d6, 470 MHz): δ 97.69 (s). Anal. calcd for
C6H3F3N6O2 + H2O: C, 27.08; H, 1.89; N, 31.58. Found: C,
27.11; H, 2.07; N, 31.36. HRMS (ESI-POS) m/z: [M + H]+
calcd for C6H4F3N6O2
+ 249.0342; found 249.0338.
2-Methyl-6-nitro-[1,2,4]triazolo[1,5-a]pyrimidine-7-amine
(2d) + H2O. Obtained from 1d (1.49 g, 10 mmol, 1 equiv) in a
mixture of fuming HNO3 (1.25 mL, 30 mmol, 3 equiv) and
H2SO4 (9.60 mL, 180 mmol, 18 equiv). Yellow solid; 1.76 g,
83% yield; mp 254−256 °C. 1H NMR (DMSO-d6, 400 MHz):
δ 2.49 (s, 3H), 9.15 (s, 1H), 9.52 (br s, 2H). 13C{1H} NMR
(DMSO-d6, 126 MHz): δ 14.7, 118.3, 145.3, 151.8, 156.0,
165.7. Anal. calcd for C6H6N6O2 + H2O: C, 33.97; H, 3.80; N,
39.61. Found: C, 33.87; H, 3.99; N, 39.78. HRMS (ESI-POS)
m/z: [M + H]+ calcd for C6H7N6O2
+ 195.0625; found
195.0625.
7-Aminopyrazolo[1,5-a]pyrimidine-3-carbonitrile (3b). A
solution of 108 mg (1 mmol) of 3-amino-4-cyanopyrazole in
dioxane 5 mL was stirred at 50 °C and treated by adding 3,3-
diethoxypropionitrile (150 μL, 1 mmol), then 36% HCl
solution (86 μL, 1 mmol). The reaction mixture was refluxed
for 2 h, the suspension was cooled to room temperature, and
the precipitate was filtered off and air-dried. The dry residue
was dissolved in H2O, the solution was stirred and adjusted
with aqueous ammonia to pH ∼ 8, and the precipitate was
filtered off and dried in a vacuum desiccator over P2O5. Beige
solid; 132 mg, 83% yield, mp >300 °C. 1H NMR (DMSO-d6,
500 MHz): δ 6.35 (d, J = 5.5 Hz, 1H), 8.24 (d, J = 5.5 Hz,
1H), 8.33 (br s, 2H), 8.64 (s, 1H). 13C{1H} NMR (DMSO-d6,
126 MHz): δ 78.4, 91.4, 114.4, 146.6, 149.1, 151.2, 152.2.
Anal. calcd for C7H5N5: C, 52.83; H, 3.17; N, 44.01. Found: C,
52.78; H, 2.99; N, 44.25.
3,6-Dinitropyrazolo[1,5-a]pyrimidine-7-amine (4). The
corresponding triazolopyrimidine-7-amine 3a,b (1 mmol)
was added portionwise to a mixture of 125 μL (3 mmol) of
Scheme 8. Preparation of Triazolo[1,5-a]pteridines 11a−d
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fuming HNO3 and 960 μL (18 mmol) of concentrated H2SO4
with stirring and cooling (ice bath). The reaction mixture was
kept at room temperature for 3 h, then poured into crushed
ice, and carefully neutralized with aqueous ammonia to pH ∼
7; the precipitate was filtered off, washed with H2O and EtOH,
and dried in a vacuum desiccator over P2O5.
Obtained from 3a (206 mg, 1 mmol, 1 equiv) in a mixture of
fuming HNO3 (125 μL, 3 mmol, 3 equiv) and H2SO4 (960 μL,
18 mmol, 18 equiv). Bright yellow solid; 202 mg, 90% yield;
mp 282−284 °C. Obtained from 3b (159 mg, 1 mmol, 1
equiv) in a mixture of fuming HNO3 (125 μL, 3 mmol, 3
equiv) and H2SO4 (960 μL, 18 mmol, 18 equiv). Bright yellow
solid; 211 mg, 94% yield; mp 283−285 °C. 1H NMR (DMSO-
d6, 600 MHz): δ 9.07 (s, 1H), 9.28 (s, 1H), 9.73 (br s, 1H),
10.07 (br s, 1H). 13C{1H} NMR (DMSO-d6, 151 MHz): δ
120.1, 124.2, 143.8, 144.3, 146.1, 152.4. Anal. calcd for
C6H4N6O4: C, 32.15; H, 1.80; N, 37.50. Found: C, 32.38; H,
1.77; N, 37.29.
3-Nitropyrazolo[1,5-a]pyrimidine-7-amine (5).10 To a
solution of 206 mg (1 mmol) of pyrazolopyrimidin-7-amine
3a in 640 μL (12 mmol) of concentrated H2SO4 with stirring
and cooling (ice bath) was added 202 mg (2 mmol) of KNO3.
The reaction mixture was kept at room temperature for 3 h,
poured into crushed ice, and carefully neutralized with aqueous
ammonia to pH ∼ 7; the precipitate was filtered off, washed
thoroughly with H2O and EtOH, and dried under reduced
pressure at 110 °C over P2O5. Bright yellow solid; 111 mg,
62% yield; mp >300 °C. 1H NMR (DMSO-d6, 500 MHz): δ
6.49 (d, J = 5.6 Hz, 1H), 8.36 (d, J = 5.6 Hz, 1H), 8.54 (br s,
2H), 8.92 (s, 1H). 13C{1H} NMR (DMSO-d6, 126 MHz): δ
93.9, 121.0, 142.2, 143.8, 149.1, 153.8. Anal. calcd for
C6H5N5O2: C, 40.23; H, 2.81; N, 39.10. Found: C, 40.49;
H, 2.85; N, 38.74.
Ethyl 7-Amino-6-nitropyrazolo[1,5-a]pyrimidine-3-car-
boxylate (6). Fuming nitric acid (1 mL) was carefully added
dropwise to acetic anhydride (2 mL) with cooling (ice bath)
and kept at room temperature for 1 h, then cooled again. To
the mixture 206 mg of pyrazolopyrimidin-7-amine 3a was
added and allowed to stand for 3 h. The reaction mixture was
poured into crushed ice and allowed to stand overnight; the
precipitate was filtered, washed with H2O, and dried in a
vacuum desiccator over P2O5. Pale yellow solid; 75 mg, 30%
yield; mp >300 °C. 1H NMR (DMSO-d6, 400 MHz): δ 1.31
(t, J = 7.1 Hz, 3H), 4.30 (q, J = 7.1 Hz, 2H), 8.66 (s, 1H), 9.15
(s, 1H), 9.53 (br s, 1H), 9.81 (br s, 1H). 13C{1H} NMR
(DMSO-d6, 101 MHz): δ 14.3, 59.8, 104.2, 118.0, 145.7,
148.0, 148.2, 149.4, 161.3. Anal. calcd for C9H9N5O4: C,
43.03; H, 3.61; N, 27.88. Found: C, 43.08; H, 3.71; N, 27.82.
General Procedure for the Synthesis of Compounds
7a−d. A mixture of corresponding 6-nitrotriazolopyrimidine-
7-amine 2a−d (1 mmol) and 10% (by weight) Pd/C (5 mol
%) in DMF (for 2a,b) or EtOH (for 2c,d) was hydrogenated
in an autoclave at 50 °C and 5−7 bar pressure of hydrogen for
5−7 h. The resulting solution/suspension was heated until the
precipitate was completely dissolved and filtered hot from Pd/
C; the solvent was removed by distillation; and the precipitate
was washed off with CHCl3, filtered, and air-dried.
[1,2,4]Triazolo[1,5-a]pyrimidine-6,7-diamine (7a). Ob-
tained from 2a (1.80 g, 10 mmol, 1 equiv), Pd/C (0.18 g,
10% by weight 2a) in DMF (50 mL). Beige solid; 1.32 g, 88%
yield; mp >300 °C. 1H NMR (DMSO-d6, 400 MHz): δ 4.50
(br s, 2H), 7.52 (br s, 2H), 8.08 (s, 1H), 8.30 (s, 1H). 13C{1H}
NMR (DMSO-d6, 101 MHz): δ 115.7, 138.9, 141.8, 151.2,
154.0. Anal. calcd for C5H6N6: C, 40.00; H, 4.03; N, 55.97.
Found: C, 39.93; H, 3.81; N, 55.82.
2-(Methylsulfonyl)-[1,2,4]triazolo[1,5-a]pyrimidine-6,7-di-
amine (7b). Obtained from 2b (2.58 g, 10 mmol, 1 equiv),
Pd/C (0.26 g, 10% by weight 2b) in DMF (50 mL). Beige
solid; 1.96 g, 86% yield; mp 265−267 °C. 1H NMR (DMSO-
d6, 500 MHz): δ 3.42 (s, 3H), 4.81 (br s, 2H), 7.91 (br s, 2H),
8.17 (s, 1H). 13C{1H} NMR (DMSO-d6, 126 MHz): δ 41.9,
118.2, 139.1, 142.3, 150.2, 163.2. Anal. calcd for C6H8N6O2S:
C, 31.58; H, 3.53; N, 36.82. Found: C, 31.77; H, 3.68; N,
36.67.
2-(Trifluoromethyl)-[1,2,4]triazolo[1,5-a]pyrimidine-6,7-
diamine (7c). Obtained from 2c (2.48 g, 10 mmol, 1 equiv),
Pd/C (0.25 g, 10% by weight 2c) in DMF (50 mL). Beige
solid; 1.92 g, 88% yield; mp 226−228 °C. 1H NMR (DMSO-
d6, 500 MHz): δ 4.77 (br s, 2H), 7.84 (br s, 2H), 8.16 (s, 1H).
13C{1H} NMR (DMSO-d6, 126 MHz): δ 117.9, 119.7 (q, J =
270.6 Hz), 139.0, 142.2, 150.6, 153.8 (q, J = 37.9 Hz). 19F
NMR (DMSO-d6, 376 MHz): δ 98.40 (s). Anal. calcd for
C6H5F3N6: C, 33.04; H, 2.31; N, 38.53. Found: C, 33.12; H,
2.34; N, 38.32.
2-Methyl-[1,2,4]triazolo[1,5-a]pyrimidine-6,7-diamine
(7d). Obtained from 2d (1.94 g, 10 mmol, 1 equiv), Pd/C
(0.19 g, 10% by weight 2d) in DMF (50 mL). Beige solid; 1.46
g, 89% yield; mp 261−263 °C. 1H NMR (DMSO-d6, 400
MHz): δ 2.39 (s, 3H), 4.42 (br s, 2H), 7.43 (br s, 2H), 7.96 (s,
1H). 13C{1H} NMR (DMSO-d6, 126 MHz): δ 14.8, 115.4,
138.6, 141.1, 151.8, 163.0. Anal. calcd for C6H8N6: C, 43.90;
H, 4.91; N, 51.19. Found: C, 43.93; H, 4.84; N, 51.44.
General Procedure for the Synthesis of Compounds
8a−d. To a solution (in case of 8d suspension) of the
corresponding triazolopyrimidin-6,7-diamine 7a−d (1 mmol)
in 4 mL of glacial AcOH (for 8b in 6 mL of a mixture of
AcOH/DMF 1:2), 0.50 mL (3 mmol) of triethyl orthoformate
was added. The reaction mixture was kept at 80 °C (for 8b at
90 °C) for 2−3 h, the suspension/solution was cooled to room
temperature, and the target product was isolated by the
method indicated for each particular compound.
1H-[1,2,4]Triazolo[5,1-b]purine (8a). The precipitate was
filtered, washed with CHCl3, and dried under reduced pressure
at 110 °C over P2O5. Obtained from 7a (150 mg, 1 mmol, 1
equiv) in a mixture of glacial AcOH (4 mL) and (EtO)3CH
(0.50 mL, 3 mmol, 3 equiv). Beige solid; 130 mg, 81% yield;
mp >300 °C. 1H NMR (DMSO-d6, 600 MHz): δ 8.63 (s, 1H),
8.64 (s, 1H), 9.20 (s, 1H), 13.92 (br s, 1H). 13C{1H} NMR
(DMSO-d6, 151 MHz): δ 119.1, 142.4, 144.5, 144.8, 154.0,
154.6. Anal. calcd for C6H4N6: C, 45.00; H, 2.52; N, 52.48.
Found: C, 45.24; H, 2.60; N, 52.33.
7-(Methylsulfonyl)-1H-[1,2,4]triazolo[5,1-b]purine (8b).
The suspension was diluted with 3 mL of H2O, and the
precipitate was filtered and dried under reduced pressure at
110 °C over P2O5. Obtained from 7b (228 mg, 1 mmol, 1
equiv) in a mixture of DMF (4 mL), glacial AcOH (2 mL),
and (EtO)3CH (0.50 mL, 3 mmol, 3 equiv). Beige solid; 169
mg, 71% yield; mp >300 °C. 1H NMR (DMSO-d6, 500 MHz):
δ 3.53 (s, 3H), 8.76 (s, 1H), 9.39 (s, 1H), 14.18 (br s, 1H).
13C{1H} NMR (DMSO-d6, 126 MHz): δ 40.1, 120.3, 144.1,
144.5, 145.3, 153.2, 163.3. Anal. calcd for C7H6N6O2S: C,
35.29; H, 2.54; N, 35.28. Found: C, 35.53; H, 2.31; N, 35.29.
7-(Trifluoromethyl)-1H-[1,2,4]triazolo[5,1-b]purine (8c).
The solvent was removed under reduced pressure, and the
precipitate was washed off with CHCl3, filtered, and dried
under reduced pressure at 110 °C over P2O5. Obtained from
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7c (218 mg, 1 mmol, 1 equiv) in a mixture of glacial AcOH (4
mL) and (EtO)3CH (0.50 mL, 3 mmol, 3 equiv). Pale yellow-
beige solid; 189 mg, 83% yield; mp 297−299 °C. 1H NMR
(DMSO-d6, 400 MHz): δ 8.75 (s, 1H), 9.38 (s, 1H), 14.17 (br
s, 1H). 13C{1H} NMR (DMSO-d6, 126 MHz): δ 119.6 (q, J =
270.4 Hz), 120.1, 144.0, 144.2, 145.2, 153.5, 153.8 (q, J = 38.6
Hz). 19F NMR (DMSO-d6, 376 MHz): δ 98.54 (s). Anal. calcd
for C7H3F3N6: C, 36.85; H, 1.33; N, 36.84. Found: C, 36.88;
H, 1.44; N, 36.72.
7-Methyl-1H-[1,2,4]triazolo[5,1-b]purine (8d). The precip-
itate was filtered, washed with CHCl3, and dried under reduced
pressure at 110 °C over P2O5. Obtained from 7d (164 mg, 1
mmol, 1 equiv) in a mixture of glacial AcOH (4 mL) and
(EtO)3CH (0.50 mL, 3 mmol, 3 equiv). Sandy solid; 159 mg,
91% yield; mp >300 °C. 1H NMR (DMSO-d6, 500 MHz): δ
2.55 (s, 3H), 8.61 (s, 1H), 9.12 (s, 1H), 13.84 (br s, 1H).
13C{1H} NMR (DMSO-d6, 126 MHz): δ 14.7, 118.4, 141.1,
143.7, 144.3, 154.0, 163.2. Anal. calcd for C7H6N6: C, 48.27;
H, 3.47; N, 48.25. Found: C, 48.16; H, 3.38; N, 48.42.
General Procedure for the Synthesis of Compounds
9a−d. To a solution/suspension of the corresponding diamine
7a−c (1 mmol) in 2 mL of DMF, 73 μL (1.2 mmol) of CS2
was added and kept close for 5 h and then excess CS2 and
dissolved H2S were distilled off using a rotary evaporator. To
the reaction mixture, 109 μL (1 mmol) of isobutyl bromide
and 139 μL (1 mmol) of triethylamine were added, the
mixture was heated to 80 °C and kept for 2 h, and the solvent
was removed under reduced pressure. The dry residue was
washed with H2O, filtered, and air-dried. Then, the dry residue
was boiled in benzene for 1 h, the suspension was cooled, and
the precipitate was filtered and air-dried.
2-[(iso-Butyl)sulfanyl]-1H-[1,2,4]triazolo[5,1-b]purine
(9a). Obtained from 7a (150 mg, 1 mmol, 1 equiv), CS2 (73
μL, 1.2 mmol, 1.2 equiv), isobutyl bromide (109 μL, 1 mmol, 1
equiv), and triethylamine (139 μL, 1 mmol, 1 equiv) in DMF
(2 mL). White solid; 182 mg, 73% yield; mp >300 °C. 1H
NMR (DMSO-d6, 500 MHz): δ 1.05 (d, J = 6.7 Hz, 6H), 2.04
(m, 1H), 3.33 (d, J = 6.8 Hz, 2H) 8.59 (s, 1H), 8.99 (s, 1H),
14.02 (br s, 1H). 13C{1H} NMR (DMSO-d6, 126 MHz): δ
21.4, 28.1, 39.7, 121.0, 139.2, 144.5, 153.2, 154.3, 155.6. Anal.
calcd for C10H12N6S: C, 48.37; H, 4.87; N, 33.85. Found: C,
48.46; H, 4.90; N, 33.69.
2-[(iso-Butyl)sulfanyl]-7-(methylsulfonyl)-1H-[1,2,4]-
triazolo[5,1-b]purine (9b). Obtained from 7b (228 mg, 1
mmol, 1 equiv), CS2 (73 μL, 1.2 mmol, 1.2 equiv), isobutyl
bromide (109 μL, 1 mmol, 1 equiv), and triethylamine (139
μL, 1 mmol, 1 equiv) in DMF (2 mL). Beige solid; 221 mg,
68% yield; mp 250−251 °C. 1H NMR (DMSO-d6, 500 MHz):
δ 1.05 (d, J = 6.7 Hz, 6H), 2.06 (m, 1H), 3.36 (d, J = 6.8 Hz,
2H) 3.51 (s, 3H), 9.15 (s, 1H), 14.28 (br s, 1H). 13C{1H}
NMR (DMSO-d6, 126 MHz): δ 21.4, 28.1, 39.8, 42.1, 122.3,
141.4, 144.7, 152.9, 157.0, 163.5. Anal. calcd for
C11H14N6O2S2: C, 40.48; H, 4.32; N, 25.75. Found: C,
40.66; H, 4.38; N, 25.58.
2-[(iso-Butyl)sulfanyl]-7-(trifluoromethyl)-1H-[1,2,4]-
triazolo[5,1-b]purine (9c). Obtained from 7c (218 mg, 1
mmol, 1 equiv), CS2 (73 μL, 1.2 mmol, 1.2 equiv), isobutyl
bromide (109 μL, 1 mmol, 1 equiv), and triethylamine (139
μL, 1 mmol, 1 equiv) in DMF (2 mL). Beige solid; 281 mg,
89% yield; mp 285−287 °C. 1H NMR (DMSO-d6 with 0.05%
v/v TMS, 400 MHz): δH δ = 1.06 (6H, d, J = 6.6 Hz,
SCH2CH(CH3)2); δ = 2.06 (1H, m, SCH2CH(CH3)2); δ =
3.35 (2H, d, J = 6.8 Hz, SCH2CH(CH3)2); δ = 9.14 (1H, s, H-
4); δ = 14.26 (1H, br s, NH). 13C NMR (DMSO-d6, 125
MHz): δC 21.4 (s, SCH2CH(CH3)2), 28.0 (s, SCH2CH-
(CH3)2), 39.7 (s, SCH2CH(CH3)2), 119.6 (q, J = 270.4 Hz,
C7), 122.1 (s, C3a), 141.1 (s, C4), 144.6 (s, C1a), 153.2 (s,
C5a), 154.0 (q, J = 38.5 Hz, CF3), 156.9 (s, C2).
19F NMR
(DMSO-d6, 470 MHz): δ 98.44 (s). Anal. calcd for
C11H11F3N6S: C, 41.77; H, 3.51; N, 26.57. Found: C, 41.90;
H, 3.59; N, 26.36.
2-[(iso-Butyl)sulfanyl]-7-methyl-1H-[1,2,4]triazolo[5,1-b]-
purine (9d). Obtained from 7d (164 mg, 1 mmol, 1 equiv),
CS2 (73 μL, 1.2 mmol, 1.2 equiv), isobutyl bromide (109 μL, 1
mmol, 1 equiv), and triethylamine (139 μL, 1 mmol, 1 equiv)
in DMF (2 mL). Beige solid; 220 mg, 84% yield; mp >300 °C.
1H NMR (DMSO-d6, 400 MHz): δ 1.04 (d, J = 6.7 Hz, 6H),
2.04 (m, 1H), 2.53 (s, 3 H), 3.32 (d, J = 6.8 Hz, 2H), 8.89 (s,
1H), 13.93 (br s, 1H). 13C{1H} NMR (DMSO-d6, 126 MHz):
δ 14.7, 21.4, 28.1, 39.7, 120.5, 138.4, 144.1, 153.6, 155.5,
163.3. Anal. calcd for C11H14N6S: C, 50.36; H, 5.38; N, 32.04.
Found: C, 50.40; H, 5.39; N, 31.99.
7-(Methylsulfonyl)-2H-[1,2,4]triazolo[1,5-a][1,2,3]triazolo-
[4,5-e]pyrimidine (10). To a suspension of 0.228 mg (1
mmol) of diamine 7b in 4 mL of ice-cold AcOH, 104 mg of
NaNO2 was added portionwise. The mixture was kept for 1 h,
and then three drops of 2 M HCl were added. The precipitate
was filtered and dried in a vacuum desiccator over KOH.
Yellow sandy solid; 139 mg, 58%; mp 248−250 °C. 1H NMR
(DMSO-d6, 500 MHz): δ 3.55 (s, 3H), 9.85 (s, 1H).
13C{1H}
NMR (DMSO-d6, 126 MHz): δ 42.1, 130.2, 143.9, 151.3,
154.3, 163.6. Anal. calcd for C6H5N7O2S: C, 30.13; H, 2.11; N,
40.99. Found: C, 30.15; H, 2.29; N, 40.82
General Procedure for the Synthesis of Compounds
11a−d. A mixture of the corresponding diamine 7a−d (1
mmol), 86 μL (1 mmol) of 36% HCl and 115 μL (1 mmol) of
40% solution of glyoxal in water were kept at 50 °C. The
reaction progress was monitored by TLC (in the CH3Cl/
CH3OH (9:1) system) for the disappearance of a spot of the
starting diamine (Rf ∼ 0.1) and formation of a spot of the
product (Rf ∼ 0.85). The target product was isolated by the
method indicated for each particular compound.
[1,2,4]Triazolo[1,5-a]pteridine (11a). The suspension was
cooled in an ice bath, the precipitate was filtered. Obtained
from 7a (150 mg, 1 mmol, 1 equiv), 40 wt % solution of
glyoxal in water (115 μL, 1 mmol, 1 equiv), 36% HCl (86 μL,
1 mmol, 1 equiv), in EtOH (5 mL). Light brown solid; 138
mg, 80% yield; mp >216−218 °C. 1H NMR (DMSO-d6, 500
MHz): δ 8.83 (s, 1H), 9.22 (d, J = 2.2 Hz, 1H), 9.24 (d, J = 2.2
Hz, 1H), 9.66 (s, 1H). 13C{1H} NMR (DMSO-d6, 101 MHz):
δ 130.1, 142.2, 145.6, 149.6, 154.8, 155.3, 159.5. Anal. calcd for
C7H4N6: C, 48.84; H, 2.34; N, 48.82. Found: C, 48.74; H,
2.51; N, 48.63.
2-(Methylsulfonyl)-[1,2,4]triazolo[1,5-a]pteridine (11b).
The suspension was cooled in an ice bath, and the precipitate
was filtered. Obtained from 7b (228 mg, 1 mmol, 1 equiv), 40
wt % solution of glyoxal in water (115 μL, 1 mmol, 1 equiv)
and 36% HCl (86 μL, 1 mmol, 1 equiv) in EtOH (5 mL).
Light brown solid; 190 mg, 76% yield; mp >229−231 °C. 1H
NMR (DMSO-d6, 500 MHz): δ 3.58 (s, 3H), 9.32 (s, 2H),
9.85 (s, 1H). 13C{1H} NMR (DMSO-d6, 126 MHz): δ 42.0,
131.8, 142.5, 146.8, 150.2, 155.0, 162.1, 164.2. Anal. calcd for
C8H6N6O2S: C, 38.40; H, 2.42; N, 33.59. Found: C, 38.27; H,
2.27; N, 33.69.
2-(Trifluoromethyl)-[1,2,4]triazolo[1,5-a]pteridine (11c).
The reaction mixture was neutralized with a 5% alcohol
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solution of KOH to pH ∼ 7 and diluted with 5 mL of MeCN;
the precipitate was filtered off and washed with 2 mL of
MeCN. The resulting filtrate was evaporated completely and
dried in a vacuum desiccator over P2O5. The dry residue was
dissolved in MeCN and filtered through a thin layer of silica
gel, the filtrate was evaporated, and the precipitate was washed
with Et2O and dried in air. Obtained from 7c (28 mg, 1 mmol,
1 equiv), 40 wt % solution of glyoxal in water (115 μL, 1
mmol, 1 equiv), 36% HCl (86 μL, 1 mmol, 1 equiv), in EtOH
(5 mL). Brown solid; 214 mg, 89% yield; mp >170−172 °C.
1H NMR (DMSO-d6, 500 MHz): 9.32 (s, 2H), 9.85 (s, 1H).
13C{1H} NMR (DMSO-d6, 126 MHz): δ 119.2 (q, J = 270.6
Hz), 131.6, 142.3, 146.7, 150.1, 154.7 (q, J = 39.2 Hz), 155.2,
161.9. 19F NMR (DMSO-d6, 470 MHz): 98.14 (s). Anal. calcd
for C8H3F3N6: C, 40.01; H, 1.26; N, 35.00. Found: C, 39.92;
H, 1.11; N, 34.88.
2-Methyl-[1,2,4]triazolo[1,5-a]pteridine (11d). The sus-
pension was cooled in an ice bath, and the precipitate was
filtered. Obtained from 7d (164 mg, 1 mmol, 1 equiv), 40 wt %
solution of glyoxal in water (115 μL, 1 mmol, 1 equiv), 36%
HCl (86 μL, 1 mmol, 1 equiv), in EtOH (5 mL). Beige solid;
148 mg, 80% yield; mp >226−228 °C. 1H NMR (DMSO-d6,
500 MHz): δ 2.61 (s, 3H), 9.17 (d, J = 2.1 Hz, 1H), 9.20 (d, J
= 2.1 Hz, 1H), 9.58 (s, 1H). 13C{1H} NMR (DMSO-d6, 126
MHz): δ 14.8, 130.6, 141.7, 145.2, 149.6, 155.0, 159.0, 164.6.
Anal. calcd for C8H6N6: C, 51.61; H, 3.25; N, 45.14. Found: C,
51.63; H, 3.16; N, 45.15.
■ ASSOCIATED CONTENT
*sı Supporting Information
The Supporting Information is available free of charge at
https://pubs.acs.org/doi/10.1021/acsomega.0c01849.
1H and 13C{1 H} NMR spectral data for the synthesized
compounds; 2D NMR (HSQC, HMBC) of 9c; HRMS
data for compounds 2c, 2d, 4, 5, and 6 (PDF)
Crystallographic data of 11a (CIF)
■ AUTHOR INFORMATION
Corresponding Author
Denis A. Gazizov − Postovsky Institute of Organic Synthesis of
Ural Branch of Russian Academy of Sciences, Ekaterinburg
620108, Russia; orcid.org/0000-0003-4820-3205;
Email: gazizov@ios.uran.ru
Authors
Evgeny B. Gorbunov − Postovsky Institute of Organic Synthesis
of Ural Branch of Russian Academy of Sciences, Ekaterinburg
620108, Russia
Gennady L. Rusinov − Postovsky Institute of Organic Synthesis
of Ural Branch of Russian Academy of Sciences, Ekaterinburg
620108, Russia; Department of Organic and Biomolecular
Chemistry, Ural Federal University, Ekaterinburg 620002,
Russia
Evgeny N. Ulomsky − Postovsky Institute of Organic Synthesis
of Ural Branch of Russian Academy of Sciences, Ekaterinburg
620108, Russia; Department of Organic and Biomolecular
Chemistry, Ural Federal University, Ekaterinburg 620002,
Russia
Valery N. Charushin − Postovsky Institute of Organic Synthesis
of Ural Branch of Russian Academy of Sciences, Ekaterinburg
620108, Russia; Department of Organic and Biomolecular
Chemistry, Ural Federal University, Ekaterinburg 620002,
Russia
Complete contact information is available at:
https://pubs.acs.org/10.1021/acsomega.0c01849
Notes
The authors declare no competing financial interest.
■ ACKNOWLEDGMENTS
The research was financially supported by the Russian Science
Foundation (project no. 19-13-00234). Analytical studies were
carried out using equipment of the Center for Joint Use
“Spectroscopy and Analysis of Organic Compounds” at the
Postovsky Institute of Organic Synthesis of UB RAS.
■ REFERENCES
(1) (a) Oukoloff, K.; Lucero, B.; Francisco, K. R.; Brunden, K. R.;
Ballatore, C. 1,2,4-Triazolo[1,5-a]pyrimidines in drug design. Eur. J.
Med. Chem. 2019, 165, 332−346. (b) Rusinov, V. L.; Charushin, V.
N.; Chupakhin, O. N. Biologically active azolo-1,2,4-triazines and
azolopyrimidines. Russ. Chem. Bull. 2018, 67, 573−599. (c) Yang, F.;
Yu, L.-Z.; Diao, P.-C.; Jian, X.-E.; Zhou, M.-F.; Jiang, C.-S.; You, W.-
W.; Ma, W.-F.; Zhao, P. L. Novel [1,2,4]triazolo[1,5-a]pyrimidine
derivatives as potent antitubulin agents: design, multicomponent
synthesis and antiproliferative activities. Bioorg. Chem. 2019, 92,
No. 103260. (d) Wan, Y.; Wu, W.; Guo, S.; He, S.; Tang, X.; Wu, X.;
Nandakumar, K. S.; Zou, M.; Li, L.; Chen, X.; Liu, S.; Yao, X.
[1,2,4]Triazolo[1,5-a]pyrimidine derivative (Mol-5) is a new NS5-
RdRp inhibitor of DENV2 proliferation and DENV2-induced
inflammation. Acta Pharmacol. Sin. 2019, 1−13. (e) Wang, S.; Shen,
D.; Zhao, L.; Yuan, X.; Cheng, J.; Yu, B.; Zheng, Y.; Liu, H. Discovery
of [1,2,4]triazolo[1,5-a]pyrimidine derivatives as new bromodomain-
containing protein 4 (BRD4) inhibitors. Chin. Chem. Lett. 2020, 31,
418−422. (f) Yuan, S.; Wang, S.; Zhao, M.; Zhang, D.; Chen, J.; Li, J.-
X.; Zhang, J.; Song, Y.; Wang, J.; Yu, B.; Liu, H. Brønsted acid-
promoted “on−water” C(sp3)-H functionalization for the synthesis of
isoindolinone/[1,2,4]triazolo[1,5-a]pyrimidine derivatives targeting
the SKP2-CKS1 interaction. Chin. Chem. Lett. 2020, 31, 349−352.
(g) Abd El-Aleam, R. H.; George, R. F.; Lee, K. J.; Keeton, A. B.;
Piazza, G. A.; Kamel, A. A.; El-Daly, M. E.; Hassan, G. S.; Abdel-
Rahman, H. M. Design and synthesis of 1,2,4-triazolo[1,5-a]-
pyrimidine derivatives as PDE 4B inhibitors endowed with
bronchodilator activity. Arch. Pharm. 2019, 352, No. 1900002.
(h) Combs, D.; Langevine, C. M.; Qiu, Y.; Zusi, F. C. U.S. Patent
WO2005011609A2, 2004.
(2) (a) Castillo, J.-C.; Estupiñan, D.; Nogueras, M.; Cobo, J.;
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